TY - JOUR
T1 - Antitumor activity of thevetoside alone and in combination with chlormethine in vivo
AU - Zhang, X. W.
AU - Huang, Z. Q.
AU - Li, C. C.
PY - 1994
Y1 - 1994
N2 - Thevetoside (TS) is one of the cardiac glycosides. A study of antitumor activity was carried out in 6 types of murine tumors in vivo, such as the ascitic tumors H22, EAC, P388, and solid tumors S180, U14, Lewis lung carcinoma, which were treated with ip TS 1.5 mg · kg-1 · d-1 alone or in combination with chlormethine (Chl) 0.3, 0.5, or 1.0 mg · kg-1 · d- 1. TS only showed a remarkable inhibition on the growth of 3 types of solid tumors with inhibition rates of 48.7% - 56.7%. The effect of the combination therapy was much pronounced than that of independent administration. The life span under combined therapy was increased 82.4% to > 122.1%. For solid tumors, the combined administration gave inhibition rates of 65.6% - 72.5%.
AB - Thevetoside (TS) is one of the cardiac glycosides. A study of antitumor activity was carried out in 6 types of murine tumors in vivo, such as the ascitic tumors H22, EAC, P388, and solid tumors S180, U14, Lewis lung carcinoma, which were treated with ip TS 1.5 mg · kg-1 · d-1 alone or in combination with chlormethine (Chl) 0.3, 0.5, or 1.0 mg · kg-1 · d- 1. TS only showed a remarkable inhibition on the growth of 3 types of solid tumors with inhibition rates of 48.7% - 56.7%. The effect of the combination therapy was much pronounced than that of independent administration. The life span under combined therapy was increased 82.4% to > 122.1%. For solid tumors, the combined administration gave inhibition rates of 65.6% - 72.5%.
UR - https://www.scopus.com/pages/publications/0028306620
M3 - 文章
C2 - 7976390
AN - SCOPUS:0028306620
SN - 0253-9756
VL - 15
SP - 285
EP - 288
JO - Acta Pharmacologica Sinica
JF - Acta Pharmacologica Sinica
IS - 3
ER -